glp-1 news 2025 october 16 Weight-Loss Drug Demonstration Begins July 2026 How the rise of GLP-1

10.1007/s13311-019-00805-5

GLP-1 medications can help lower inflammation and support weight loss, both of which are important in PsA

No, yeast infections are not listed as a recognized side effect in FDA prescribing information for Zepbound, and clinical trials did not identify them as a statistically significant adverse event directly attributable to tirzepatide

97 When assessing seizure and epilepsy separately, newer agents significantly lowered the risk of seizure (RR = 0.78, 95% CI: 0.601.00

Once-Weekly semaglutide in adults with overweight or obesity

17 In addition to these findings, the SUSTAIN-6 trial also showed that semaglutide can offer a significant reduction in the risk of new or worsening nephropathy including persistent macroalbuminuria, increase in serum creatinine or the need of renal replacement therapy